Gilder Gagnon Howe & Co. LLC purchased a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 16,678 shares of the biotechnology company's stock, valued at approximately $671,000.
A number of other institutional investors have also recently modified their holdings of the business. Syon Capital LLC acquired a new position in Viking Therapeutics during the fourth quarter worth $312,000. J. Safra Sarasin Holding AG acquired a new position in Viking Therapeutics during the fourth quarter worth $552,000. Stifel Financial Corp raised its holdings in Viking Therapeutics by 36.1% during the fourth quarter. Stifel Financial Corp now owns 178,819 shares of the biotechnology company's stock worth $7,196,000 after purchasing an additional 47,471 shares during the last quarter. OneDigital Investment Advisors LLC raised its holdings in Viking Therapeutics by 59.2% during the fourth quarter. OneDigital Investment Advisors LLC now owns 5,189 shares of the biotechnology company's stock worth $209,000 after purchasing an additional 1,929 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in Viking Therapeutics by 46.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 13,923 shares of the biotechnology company's stock worth $560,000 after purchasing an additional 4,433 shares during the last quarter. 76.03% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at Viking Therapeutics
In other Viking Therapeutics news, Director Sarah Kathryn Rouan purchased 1,240 shares of the company's stock in a transaction on Monday, March 31st. The shares were purchased at an average cost of $24.15 per share, for a total transaction of $29,946.00. Following the completion of the transaction, the director now owns 1,240 shares in the company, valued at $29,946. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.10% of the company's stock.
Viking Therapeutics Price Performance
Shares of NASDAQ:VKTX traded up $0.93 during midday trading on Wednesday, reaching $28.87. The company had a trading volume of 5,235,364 shares, compared to its average volume of 4,096,974. The stock's fifty day moving average price is $26.17 and its 200-day moving average price is $39.90. The stock has a market capitalization of $3.24 billion, a P/E ratio of -28.87 and a beta of 0.84. Viking Therapeutics, Inc. has a one year low of $18.92 and a one year high of $81.86.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). The company's revenue for the quarter was up .0% on a year-over-year basis. During the same period last year, the company posted ($0.26) EPS. As a group, sell-side analysts forecast that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current year.
Wall Street Analysts Forecast Growth
VKTX has been the topic of several recent research reports. HC Wainwright restated a "buy" rating and issued a $102.00 price objective on shares of Viking Therapeutics in a research report on Thursday, April 24th. Piper Sandler reduced their price objective on Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating on the stock in a research report on Thursday, February 6th. Raymond James increased their target price on Viking Therapeutics from $122.00 to $125.00 and gave the stock a "strong-buy" rating in a research report on Thursday, February 6th. Citigroup initiated coverage on Viking Therapeutics in a research report on Friday, February 7th. They set a "neutral" rating and a $38.00 target price on the stock. Finally, Scotiabank initiated coverage on Viking Therapeutics in a research report on Thursday, February 13th. They set a "sector outperform" rating and a $102.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $87.15.
Read Our Latest Research Report on VKTX
About Viking Therapeutics
(
Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Further Reading
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
